A5025944204- SARS-CoV-2 and COVID-19 Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Optimism, Hope, and Well-being
- Systemic Sclerosis and Related Diseases
- Antifungal resistance and susceptibility
- Long-Term Effects of COVID-19
- Healthcare Systems and Public Health
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- Peripheral Neuropathies and Disorders
- Drug-Induced Adverse Reactions
- Human Health and Disease
- Dermatological and COVID-19 studies
- Animal Virus Infections Studies
- Cardiovascular Health and Risk Factors
- Intramuscular injections and effects
- COVID-19 and Mental Health
Washington University in St. Louis
2021-2023
Patients with chronic inflammatory disease (CID) treated immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides protection in immunocompetent persons, immunogenicity immunosuppressed patients CID is unclear.To determine the of vaccines CID.Prospective observational cohort study.Two U.S. referral centers.Volunteer sample adults confirmed eligible early COVID-19 vaccination, including hospital employees any age and older than...
ABSTRACT Background Individuals with chronic inflammatory diseases (CID) are frequently treated immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2 vaccination platforms provide robust protection in immunocompetent individuals, the immunogenicity CID patients on immunosuppression is not well established. Therefore, determining effectiveness vaccines setting essential to risk-stratify impaired and clinical guidance regarding...
Objective Little is known regarding the reactogenicity and related SARS–CoV‐2 vaccine response in patients with chronic inflammatory disease (CID). Our objective was to characterize adverse event profile of CID following vaccination understand relationship between immunogenicity vaccines. Methods healthy controls eligible receive messenger RNA (mRNA) vaccines participated 3 study visits (pre‐vaccine, after dose 1, 2) which blood clinical data were collected. Assessment events solicited...
Immunocompromised patients with chronic inflammatory disease (CID) may have experienced additional psychosocial burden during the COVID-19 pandemic due to their immunocompromised status. This study was undertaken determine if vaccination would result in improved patient-reported outcomes longitudinally among individuals CID undergoing SARS-CoV-2 regardless of baseline anxiety.
<h3>Background</h3> Patients with SLE experience substantial health disparities. Studying the effect of spatial context on outcomes has become a focus in disparities research. The CDC Social Vulnerability Index (SVI) characterizes census tracts by individual dimensions social vulnerability, which create cumulative SVI capable identifying communities where determinants lead to higher levels morbidity and mortality. <h3>Objectives</h3> We sought understand level vulnerability patients reside...
<h3>Background</h3> Patients with SLE experience substantial health disparities. Studying the effect of spatial context on outcomes has become a focus in disparities research. The CDC Social Vulnerability Index (SVI) identifies communities where social determinants lead to higher levels morbidity and mortality. We sought understand level vulnerability patients reside determine if specific dimensions were associated disease activity prednisone utilization. <h3>Methods</h3> 272 consented...